Clinical Trial Update: Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of apalutamide and cetrelimab in treatment-emergent small cell neuroendocrine prostate cancer was terminated, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Small Cell Carcinoma
• Small Cell Neuroendocrine Carcinoma

Drugs mentioned

• Cetrelimab
• ERLEADA (apalutamide)

Snippet

Sponsor: Rahul Aggarwal | Conditions: Small Cell Neuroendocrine Carcinoma, Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-05-15